Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.

Abstract

The aim of the study was to investigate the therapeutic activity of Fludarabine in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) no longer responding to standard treatment. In this Phase II study patients were treated with Fludarabine 25 mg/m2 intravenously daily for 5 days repeated at 28-day intervals. Twenty-two patients with LG-NHL, no longer responding to standard treatment, were entered in the study. Among twenty-one evaluable patients, seven had a complete and six a partial response. The median time to treatment failure and survival time are 4.6 months and >28.0 months, respectively. The most important toxicity was hemogram suppression, which was usually manageable but occasionally severe. Fludarabine is not only an active agent with definite therapeutic value in patients with treatment-resistant LG-NHL, but effective and well tolerated in patients no longer responding to standard treatment.

• Authors: C I Falkson
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 19 Issue 3 Pg. 268-70 (Jun 1996) ISSN: 0277-3732 [Print] United States
• PMID: 8638539 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Vidarabine
• fludarabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (adverse effects, therapeutic use)
• Female
• Humans
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Vidarabine (adverse effects, analogs & derivatives, therapeutic use)